drugset / Trial / NCT03332329
Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients
NaSingle-groupOpen-labelTreatment
Summary
The aim of the prospective study is to determine whether combination/ sequential therapy with Entecavir, Peginterferon alfa-2b and immunomodulators Granulocyte Macrophage Colony Stimulating Factor (GMCSF)+vaccine could induce HBsAg loss in chronic hepatitis B patients with maintained Hepatitis B Virus (HBV) DNA suppression on long-term nucleoside or nucleotide analogue (NA).
Timeline
- Start
- 2015-12-01
- Primary completion
- 2018-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entecavir | Small molecule | — | — |
| Subject | Granulocyte-Macrophage Colony-Stimulating Factor | Protein / enzyme biologic | 75 ug | Subcutaneous |
| Subject | HBV vaccine | Vaccine | 60 ug | — |
| Subject | Ypeginterferon alfa-2b | Protein / enzyme biologic | 180 ug | Subcutaneous |